Cargando…
318. Beta-lactam Therapeutic Drug Monitoring Improves Attainment of Target Drug Levels in Critically Ill Patients
BACKGROUND: Critically ill patients, particularly those treated with extracorporeal devices or at extremes of weight, experience pharmacokinetic variability which can compromise beta-lactam (BL) antibiotic target attainment and treatment response. Therapeutic drug monitoring (TDM) for BL antibiotics...
Autores principales: | Ausman, Sara, Braga, Shienna, Hagy, Natalie T, Rivera (O'Connor), Christina G, Moreland-Head, Lindsay, Rebecca, Wessel, Abu Saleh, Omar M, Rule, Andrew D, Gajic, ognjen, Barreto, Erin F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676988/ http://dx.doi.org/10.1093/ofid/ofad500.389 |
Ejemplares similares
-
743. Implementation of Beta-Lactam Therapeutic Drug Monitoring Programs in the Critically Ill: A Multicenter Mixed-Methods Study
por: Ausman, Sara, et al.
Publicado: (2022) -
Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study
por: Barreto, Erin F., et al.
Publicado: (2021) -
Explorative Study on Isolation and Characterization of a Microviridae G4 Bacteriophage, EMCL318, against Multi-Drug-resistant Escherichia coli 15-318
por: Ghosh, Soumya, et al.
Publicado: (2018) -
Deciphering the streamlined genome of Streptomyces xiamenensis 318 as the producer of the anti-fibrotic drug candidate xiamenmycin
por: XU, Min-Juan, et al.
Publicado: (2016) -
Beta-Lactam Probability of Target Attainment Success: Cefepime as a Case Study
por: Selig, Daniel J., et al.
Publicado: (2023)